The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

Nisha C. Kakodkar; Radhika Peddinti; Morris Kletzel; Yufeng Tian; Lisa J. Guerrero; Samir D. Undevia; David Geary; Alexandre Chlenski; Qiwei Yang; Helen R. Salwen; Susan L. Cohn

doi:10.1002/pbc.22639

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

Nisha C. Kakodkar, Radhika Peddinti, Morris Kletzel, Yufeng Tian, Lisa J. Guerrero, Samir D. Undevia, David Geary, Alexandre Chlenski, Qiwei Yang, Helen R. Salwen, Susan L. Cohn

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G₂ cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.

Original language	English (US)
Pages (from-to)	164-167
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	56
Issue number	1
DOIs	https://doi.org/10.1002/pbc.22639
State	Published - Jan 2011
Externally published	Yes

Keywords

Neuroblastoma
Phase I
Relapse
Topoisomerase inhibitor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.22639

Cite this

@article{48618cc602cc4bef9691bd73824700da,

title = "The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth",

abstract = "The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G2 cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.",

keywords = "Neuroblastoma, Phase I, Relapse, Topoisomerase inhibitor",

author = "Kakodkar, {Nisha C.} and Radhika Peddinti and Morris Kletzel and Yufeng Tian and Guerrero, {Lisa J.} and Undevia, {Samir D.} and David Geary and Alexandre Chlenski and Qiwei Yang and Salwen, {Helen R.} and Cohn, {Susan L.}",

year = "2011",

month = jan,

doi = "10.1002/pbc.22639",

language = "English (US)",

volume = "56",

pages = "164--167",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

AU - Kakodkar, Nisha C.

AU - Peddinti, Radhika

AU - Kletzel, Morris

AU - Tian, Yufeng

AU - Guerrero, Lisa J.

AU - Undevia, Samir D.

AU - Geary, David

AU - Chlenski, Alexandre

AU - Yang, Qiwei

AU - Salwen, Helen R.

AU - Cohn, Susan L.

PY - 2011/1

Y1 - 2011/1

N2 - The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G2 cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.

AB - The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G2 cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.

KW - Neuroblastoma

KW - Phase I

KW - Relapse

KW - Topoisomerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=78649638205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649638205&partnerID=8YFLogxK

U2 - 10.1002/pbc.22639

DO - 10.1002/pbc.22639

M3 - Article

C2 - 20860039

AN - SCOPUS:78649638205

SN - 1545-5009

VL - 56

SP - 164

EP - 167

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

ER -

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this